Prevention of Venous Thromboembolism after Total Hip or Knee Replacement
In brief
Aspirin fails to match anticoagulants for clot prevention after joint replacement
In a trial of 15,317 hip or knee replacement patients, death or symptomatic blood clots occurred within six months in 1.26% taking aspirin, 1.23% taking warfarin and 0.94% taking rivaroxaban. Aspirin did not meet the trial's standard for being no worse than either anticoagulant, but the low event rates leave the size of any difference uncertain.
- Journal
- The New England journal of medicine (Q1)
- Published
- 12 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Vincent D Pellegrini, Carol A Lambourne, Laurence S Magder, Patricia D Franklin, Jay S Magaziner, Brook I Martin, et al.
- PMID
- 43013818
- DOI
- 10.1056/NEJMoa2602435
Why clinicians should know about it
- Picked for Orthopedics and Sports Medicine (top studies of the week, 15 November 2026): Large randomized trial compares thromboprophylaxis after hip and knee replacement
Abstract
BACKGROUND: Studies comparing aspirin with anticoagulants for venous thromboembolism (VTE) prophylaxis after total hip or knee arthroplasty have had conflicting results. METHODS: In a comparative-effectiveness noninferiority trial, we randomly assigned patients undergoing elective hip or knee arthroplasty to receive aspirin (81 mg twice daily), warfarin (to a target international normalized ratio of 2.0), or rivaroxaban (10 mg daily) for 30 days. The composite primary effectiveness outcome (death from any cause or symptomatic VTE) and primary safety outcome (bleeding, reoperation for wound problems, or myocardial infarction) were evaluated through 6 months in a blinded fashion. The noninferiority margin for the risk difference was 0.69 percentage points. RESULTS: Among 18,883 participants who had undergone randomization, 15,317 (7214 with hip arthroplasty and 8103 with knee arthroplasty) were included in the primary per-protocol analysis. A primary effectiveness outcome event occurred in 77 of 6090 participants (1.26%) in the aspirin group, in 52 of 4231 (1.23%) in the warfarin group, and in 47 of 4996 (0.94%) in the rivaroxaban group; a primary safety outcome event occurred in 177 (2.91%), 142 (3.36%), and 174 (3.48%), respectively. In pairwise comparisons, 6-month risks of a primary effectiveness outcome event were 1.24% and 0.94% for aspirin versus rivaroxaban (difference, 0.30 percentage points; 95% confidence interval [CI], -0.20 to 0.81); 1.24% and 1.01% for aspirin versus warfarin (difference, 0.23 percentage points; 95% CI, -0.34 to 0.81); and 1.13% and 1.10% for warfarin versus rivaroxaban (difference, 0.03 percentage points; 95% CI, -0.57 to 0.63). Risks of a primary safety outcome event were 3.70% and 3.02% for rivaroxaban versus aspirin (difference, 0.68 percentage points; 95% CI, -0.04 to 1.41); 3.65% and 2.88% for warfarin versus aspirin (difference, 0.77 percentage points; 95% CI, -0.04 to 1.58); and 3.59% and 3.61% for rivaroxaban versus warfarin (difference, -0.02 percentage points; 95% CI, -0.89 to 0.85). Intention-to-treat analyses yielded similar results. CONCLUSIONS: Aspirin prophylaxis after total hip or knee arthroplasty was not noninferior to rivaroxaban or warfarin with respect to death or symptomatic VTE. Warfarin and rivaroxaban were not noninferior to aspirin for safety. (Funded by the Patient-Centered Outcomes Research Institute; PEPPER ClinicalTrials.gov number, NCT02810704.).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.